Indraprastha Medical Corporation Posts 14% Profit Growth in FY26

Profit for the Year: Rs 183.62 Crore | Dividend per Share: Rs 4

Reader Takeaway: Strong operational growth and consistent dividends are tempered by long-standing, sub-judice litigation regarding free treatment mandates.

What just happened

Indraprastha Medical Corporation Limited (IMCL) released its FY26 annual report, showing a robust financial performance. Revenue from operations reached Rs 1,482.51 crore, a 9.3% increase over the previous year. Profit after tax rose by 14% to Rs 183.62 crore, resulting in an EPS of Rs 20.03. The Board has recommended a dividend of Rs 4 per share, with the record date set for September 18, 2026.

Why this matters

The company’s ability to grow profit by 14% amidst a capital-intensive healthcare environment reflects operational efficiency. The expansion of its robotic surgery network to 42 systems and high engagement on digital platforms like Apollo 24/7 suggest sustainable long-term growth drivers. Reaffirmed [ICRA]AA (stable) ratings further underline the firm's financial stability.

Risks to watch

A significant long-term challenge is the ongoing Public Interest Litigation (PIL) regarding free treatment requirements. While the company is complying with interim orders from the Delhi High Court and Supreme Court, the final resolution of this case remains a material regulatory risk that investors should monitor closely.

Board and Governance Update

The company underwent board restructuring, appointing Mr. Sudhir Jalan and Mr. Harsh Pati Singhania as Independent Directors. Dr. Menaka Guruswamy, Dr. Arun Rai, and Mr. Vinayak Chatterjee have stepped down. These shifts mark a notable transition in the firm's governance oversight.

What to track next

The 38th Annual General Meeting, scheduled for September 24, 2026, will be the next major touchpoint for shareholders to gain insights into management's future outlook and strategic roadmap.